JAK2 and essential thrombocythemia: A frequent common factor for the 3 subtypes of MPNs is the driver mutation JAK2 V617F (hereinafter referred to as just JAK2) which is present in approximately 55% of ET patients, 98% of PV patients and 60% of PMF patients (3).